Sunitinib inhibits lymphatic endothelial cell functions and lymph node metastasis in a breast cancer model through inhibition of vascular endothelial growth factor receptor 3

Breast Cancer Research

Volumn 13, Issue 3, 2011, Pages

  Kodera, Yasuo ^a,b   Katanasaka, Yasufumi ^c   Kitamura, Yuka ^a   Tsuda, Hitoshi ^a   Nishio, Kazuto ^b   Tamura, Tomohide ^a   Koizumi, Fumiaki ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c UNIVERSITY OF SHIZUOKA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

LUCIFERASE; MONOCLONAL ANTIBODY DC101; SUNITINIB; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3; ANGIOGENESIS INHIBITOR; INDOLE DERIVATIVE; PYRROLE DERIVATIVE; VASCULOTROPIN C; VASCULOTROPIN D;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER CELL; CANCER MODEL; CELL FUNCTION; CELL GROWTH; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; ENDOTHELIUM CELL; FEMALE; IN VIVO STUDY; LYMPH NODE METASTASIS; LYMPH VESSEL; LYMPHANGIOGENESIS; MICROVASCULATURE; MOUSE; NONHUMAN; PROTEIN PHOSPHORYLATION; ANIMAL; CELL MOTION; DRUG ANTAGONISM; EXPERIMENTAL NEOPLASM; HUMAN; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PHOSPHORYLATION;

ANGIOGENESIS INHIBITORS; ANIMALS; CELL MOVEMENT; ENDOTHELIAL CELLS; FEMALE; HUMANS; INDOLES; LYMPHANGIOGENESIS; LYMPHATIC METASTASIS; LYMPHATIC VESSELS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHORYLATION; PYRROLES; VASCULAR ENDOTHELIAL GROWTH FACTOR C; VASCULAR ENDOTHELIAL GROWTH FACTOR D; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-3;

EID: 79959278619     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr2903     Document Type: Article

References (34)

1. Gupta GP, Massague J. Cancer metastasis: building a framework. Cell 2006, 127:679-695. 10.1016/j.cell.2006.11.001, 17110329.
2. Stacker SA, Achen MG, Jussila L, Baldwin ME, Alitalo K. Lymphangiogenesis and cancer metastasis. Nat Rev Cancer 2002, 2:573-583. 10.1038/nrc863, 12154350.
3. Alitalo K, Tammela T, Petrova TV. Lymphangiogenesis in development and human disease. Nature 2005, 438:946-953. 10.1038/nature04480, 16355212.
4. Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. Nat Rev Cancer 2009, 9:239-252. 10.1038/nrc2618, 19279573.
5. Tammela T, Alitalo K. Lymphangiogenesis: molecular mechanisms and future promise. Cell 2010, 140:460-476. 10.1016/j.cell.2010.01.045, 20178740, 20178740.
6. Achen MG, McColl BK, Stacker SA. Focus on lymphangiogenesis in tumor metastasis. Cancer Cell 2005, 7:121-127. 10.1016/j.ccr.2005.01.017, 15710325.
7. Adams RH, Alitalo K. Molecular regulation of angiogenesis and lymphangiogenesis. Nat Rev Mol Cell Biol 2007, 8:464-478. 10.1038/nrm2183, 17522591.
8. Zwaans BM, Bielenberg DR. Potential therapeutic strategies for lymphatic metastasis. Microvasc Res 2007, 74:145-158. 10.1016/j.mvr.2007.08.006, 2525453, 17950368.
9. Skobe M, Hawighorst T, Jackson DG, Prevo R, Janes L, Velasco P, Riccardi L, Alitalo K, Claffey K, Detmar M. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med 2001, 7:192-198. 10.1038/84643, 11175850.
10. Stacker SA, Caesar C, Baldwin ME, Thornton GE, Williams RA, Prevo R, Jackson DG, Nishikawa S, Kubo H, Achen MG. VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat Med 2001, 7:186-191. 10.1038/84635, 11175849.
11. Podgrabinska S, Braun P, Velasco P, Kloos B, Pepper MS, Skobe M. Molecular characterization of lymphatic endothelial cells. Proc Natl Acad Sci USA 2002, 99:16069-16074. 10.1073/pnas.242401399, 138566, 12446836.
12. Zeng Y, Opeskin K, Goad J, Williams ED. Tumor-induced activation of lymphatic endothelial cells via vascular endothelial growth factor receptor-2 is critical for prostate cancer lymphatic metastasis. Cancer Res 2006, 66:9566-9575. 10.1158/0008-5472.CAN-06-1488, 17018613.
13. Wissmann C, Detmar M. Pathways targeting tumor lymphangiogenesis. Clin Cancer Res 2006, 12:6865-6868. 10.1158/1078-0432.CCR-06-1800, 17145802.
14. Dumont DJ, Jussila L, Taipale J, Lymboussaki A, Mustonen T, Pajusola K, Breitman M, Alitalo K. Cardiovascular failure in mouse embryos deficient in VEGF receptor-3. Science 1998, 282:946-949.
15. Mäkinen T, Jussila L, Veikkola T, Karpanen T, Kettunen MI, Pulkkanen KJ, Kauppinen R, Jackson DG, Kubo H, Nishikawa S, Ylä-Herttuala S, Alitalo K. Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3. Nat Med 2001, 7:199-205. 10.1038/84651, 11175851.
16. Kriehuber E, Breiteneder-Geleff S, Groeger M, Soleiman A, Schoppmann SF, Stingl G, Kerjaschki D, Maurer D. Isolation and characterization of dermal lymphatic and blood endothelial cells reveal stable and functionally specialized cell lineages. J Exp Med 2001, 194:797-808. 10.1084/jem.194.6.797, 2195953, 11560995.
17. Saaristo A, Veikkola T, Enholm B, Hytönen M, Arola J, Pajusola K, Turunen P, Jeltsch M, Karkkainen MJ, Kerjaschki D, Bueler H, Ylä-Herttuala S, Alitalo K. Adenoviral VEGF-C overexpression induces blood vessel enlargement, tortuosity, and leakiness but no sprouting angiogenesis in the skin or mucous membranes. Faseb J 2002, 16:1041-1049. 10.1096/fj.01-1042com, 12087065.
18. Goldman J, Rutkowski JM, Shields JD, Pasquier MC, Cui Y, Schmokel HG, Willey S, Hicklin DJ, Pytowski B, Swartz MA. Cooperative and redundant roles of VEGFR-2 and VEGFR-3 signaling in adult lymphangiogenesis. FASEB J 2007, 21:1003-1012. 10.1096/fj.06-6656com, 17210781.
19. He Y, Kozaki K, Karpanen T, Koshikawa K, Yla-Herttuala S, Takahashi T, Alitalo K. Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling. J Natl Cancer Inst 2002, 94:819-825.
20. Roberts N, Kloos B, Cassella M, Podgrabinska S, Persaud K, Wu Y, Pytowski B, Skobe M. Inhibition of VEGFR-3 activation with the antagonistic antibody more potently suppresses lymph node and distant metastases than inactivation of VEGFR-2. Cancer Res 2006, 66:2650-2657. 10.1158/0008-5472.CAN-05-1843, 16510584.
21. Burton JB, Priceman SJ, Sung JL, Brakenhielm E, An DS, Pytowski B, Alitalo K, Wu L. Suppression of prostate cancer nodal and systemic metastasis by blockade of the lymphangiogenic axis. Cancer Res 2008, 68:7828-7837. 10.1158/0008-5472.CAN-08-1488, 2800077, 18829538.
22. Matsui J, Funahashi Y, Uenaka T, Watanabe T, Tsuruoka A, Asada M. Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase. Clin Cancer Res 2008, 14:5459-5465. 10.1158/1078-0432.CCR-07-5270, 18765537.
23. Heckman CA, Holopainen T, Wirzenius M, Keskitalo S, Jeltsch M, Yla-Herttuala S, Wedge SR, Jurgensmeier JM, Alitalo K. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis. Cancer Res 2008, 68:4754-4762. 10.1158/0008-5472.CAN-07-5809, 18559522.
24. Schomber T, Zumsteg A, Strittmatter K, Crnic I, Antoniadis H, Littlewood-Evans A, Wood J, Christofori G. Differential effects of the vascular endothelial growth factor receptor inhibitor PTK787/ZK222584 on tumor angiogenesis and tumor lymphangiogenesis. Mol Cancer Ther 2009, 8:55-63. 10.1158/1535-7163.MCT-08-0679, 19139113.
25. Faivre S, Demetri G, Sargent W, Raymond E. Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov 2007, 6:734-745. 10.1038/nrd2380, 17690708.
26. Jenkins DE, Hornig YS, Oei Y, Dusich J, Purchio T. Bioluminescent human breast cancer cell lines that permit rapid and sensitive in vivo detection of mammary tumors and multiple metastases in immune deficient mice. Breast Cancer Res 2005, 7:R444-454. 10.1186/bcr1026, 1175057, 15987449.
27. Fukai J, Nishio K, Itakura T, Koizumi F. Antitumor activity of cetuximab against malignant glioma cells overexpressing EGFR deletion mutant variant III. Cancer Sci 2008, 99:2062-2069.
28. Dixelius J, Makinen T, Wirzenius M, Karkkainen MJ, Wernstedt C, Alitalo K, Claesson-Welsh L. Ligand-induced vascular endothelial growth factor receptor-3 (VEGFR-3) heterodimerization with VEGFR-2 in primary lymphatic endothelial cells regulates tyrosine phosphorylation sites. J Biol Chem 2003, 278:40973-40979. 10.1074/jbc.M304499200, 12881528.
29. Alam A, Herault JP, Barron P, Favier B, Fons P, Delesque-Touchard N, Senegas I, Laboudie P, Bonnin J, Cassan C, Savi P, Ruggeri B, Carmeliet P, Bono F, Herbert JM. Heterodimerization with vascular endothelial growth factor receptor-2 (VEGFR-2) is necessary for VEGFR-3 activity. Biochem Biophys Res Commun 2004, 324:909-915. 10.1016/j.bbrc.2004.08.237, 15474514.
30. Morelli MP, Brown AM, Pitts TM, Tentler JJ, Ciardiello F, Ryan A, Jurgensmeier JM, Eckhardt SG. Targeting vascular endothelial growth factor receptor-1 and -3 with cediranib (AZD2171): effects on migration and invasion of gastrointestinal cancer cell lines. Mol Cancer Ther 2009, 8:2546-2558. 10.1158/1535-7163.MCT-09-0380, 2819052, 19755510.
31. Blansfield JA, Caragacianu D, Alexander HR, Tangrea MA, Morita SY, Lorang D, Schafer P, Muller G, Stirling D, Royal RE, Libutti SK. Combining agents that target the tumor microenvironment improves the efficacy of anticancer therapy. Clin Cancer Res 2008, 14:270-280. 10.1158/1078-0432.CCR-07-1562, 18172279.
32. Zhang L, Smith KM, Chong AL, Stempak D, Yeger H, Marrano P, Thorner PS, Irwin MS, Kaplan DR, Baruchel S. In vivo antitumor and antimetastatic activity of sunitinib in preclinical neuroblastoma mouse model. Neoplasia 2009, 11:426-435. 2671855, 19412427.
33. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009, 15:232-239. 10.1016/j.ccr.2009.01.021, 19249681.
34. Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vinals F, Inoue M, Bergers G, Hanahan D, Casanovas O. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009, 15:220-231. 10.1016/j.ccr.2009.01.027, 2874829, 19249680.